LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

Kodu・Aktsiate loetelu・Avalo Therapeutics
Search

Avalo Therapeutics

Avatud

19.46 -1.12

Tugev "osta" hinnang

Hinna uuendus 14. mai 2026, 14:12 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.05

Max

20.04

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+135.16% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

15. mai 2026

Avalo Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 22:54 UTC

Tulu

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

DJ

Loe

13. mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

13. mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

DJ

Loe

13. mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

DJ

Loe

13. mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

13. mai 2026, 23:17 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

DJ

Loe

13. mai 2026, 23:16 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

DJ

Loe

13. mai 2026, 23:15 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

DJ

Loe

13. mai 2026, 23:14 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

DJ

Loe

13. mai 2026, 23:02 UTC

Market Talk
Tulu

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

DJ

Loe

13. mai 2026, 22:59 UTC

Market Talk
Tulu

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

DJ

Loe

13. mai 2026, 22:24 UTC

Tulu

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

DJ

Loe

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Organic Revenue Growth 25%>XRO.AU

DJ

Loe

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Revenue Growth 47%>XRO.AU

DJ

Loe

13. mai 2026, 22:22 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

DJ

Loe

13. mai 2026, 22:19 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

DJ

Loe

13. mai 2026, 22:19 UTC

Tulu

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

DJ

Loe

13. mai 2026, 22:18 UTC

Tulu

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

DJ

Loe

13. mai 2026, 22:16 UTC

Tulu

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

DJ

Loe

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

DJ

Loe

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

DJ

Loe

13. mai 2026, 22:13 UTC

Tulu

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

DJ

Loe

13. mai 2026, 22:12 UTC

Tulu

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

DJ

Loe

13. mai 2026, 22:11 UTC

Tulu

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

DJ

Loe

13. mai 2026, 22:11 UTC

Tulu

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

DJ

Loe

13. mai 2026, 22:10 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

DJ

Loe

13. mai 2026, 22:10 UTC

Tulu

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

DJ

Loe

13. mai 2026, 22:09 UTC

Tulu

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

DJ

Loe

13. mai 2026, 22:00 UTC

Tulu

Cisco to Shed Jobs for All-In AI Push -- Update

DJ

Loe

13. mai 2026, 21:11 UTC

Tulu

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Avalo Therapeutics Prognoos

Hinnasiht

By TipRanks

135.16% tõus

12 kuu keskmine prognoos

Keskmine 46.89 USD  135.16%

Kõrge 62 USD

Madal 29 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Avalo Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

9

Osta

0

Hoia

0

Müü

Põhineb 9 analüütiku instrumendi Avalo Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

$

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,008.17

↑ +0.84%

JNJ

Johnson and Johnson

231.28

↑ +1.24%

ABBV

AbbVie Inc

212

↑ +2.62%

UNH

UnitedHealth Group Inc

399.28

↑ +0.45%

AZN

AstraZeneca PLC

185.47

↓-0.15%
help-icon Live chat